Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0308 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0273 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0308 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0308 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0153 | 0 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0308 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0153 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0308 | 1 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.8532 | 0.8066 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0308 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0308 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0308 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0308 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0308 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0308 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0308 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0308 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0308 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.8532 | 0.8066 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.019 | 0.2407 | 0.2407 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0155 | 0.0151 | 0.0151 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0308 | 1 | 0.5 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.8532 | 0.8066 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0308 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0308 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0308 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0273 | 0.7743 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.019 | 0.2407 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0308 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0308 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0308 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0308 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0286 | 0.8532 | 0.8066 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID485386, AID504448, AID504454, AID504459] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.